Researchers are developing a consensus report to provide clinical guidance for the management of patients with chronic non cancer pain who are taking both opioids and cannabinoids.
Preoperative and postoperative process changes lead to faster recovery without increased pain.
Physician anesthesiologists concerned about prevalent misunderstanding about marijuana, related products.
Growth parameters similar to those for newborns of women with opioid use disorders during pregnancy.
But evidence insufficient to assess impact of many treatments to reduce headache frequency in youth.
Evidence inadequate to weigh the balance of benefits and harms of screening for adolescents.
A ten-week outpatient Acceptance and Commitment Therapy (ACT)-based interdisciplinary pain rehabilitation program for individuals with chronic pain was associated with improvements that included pain severity, pain interference, and physical and mental health-related quality of life.
Patients’ perceptions of pain, pain medication may affect prescribing practices.
Collaborative care led by a nurse-physician team with web-based self-management better than self-management alone.
Agency says unproven claims about CBD products could lead consumers to delay medical care.
Odds of long-term opioid use up with initial Rx for 5- to 9-day supply vs supply of less than 5 days.
No reduction seen in individual-level nonmedical prescription opioid use from 2002 to 2014.
Most common effects include agitation, tachycardia, drowsiness, vomiting, confusion.
Retail customers report decreases in prescriptions, over-the-counter meds due to effectiveness of cannabis.
The US Food and Drug Administration is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.
Buprenorphine treatment may be more available to individuals who are white, use self-pay, or have private insurance.
Only 1.5% of high-risk patients are prescribed naloxone upon ED or inpatient discharge.
Organization claims guidelines influenced by people with financial ties to Purdue Pharma.
The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
Misapplication of the guideline can put patient health and safety at risk.